European Commission logo
English English
CORDIS - EU research results

iMOTED Platform Built to improve Clinical Trial outcomes

Project description

Novel customisable platform for predicting clinical trial outcomes

Treatment plans, drugs and devices destined for human use must first be tested in clinical studies, a time-consuming and costly process. Clinical trial success does not only rely on science but is largely dependent on the initial design, development and management process. To improve clinical trial outcomes, the EU-funded iMOTED project has developed software that combines real-time data from multiple sources to simulate and predict clinical trial results. The iMOTED platform is simple to implement and is expected to assist the industry in launching new therapeutics by minimising associated economic losses.


Clinical Trials (CT) are designed to prove if a drug, device or therapy is safe and effective in the human body, so they are already tested in individuals. The CT investigators and sponsors spend great amount of resources on data management and project and data quality control. In 2017 more than 120,000 CT have been registered, of which near 31,000 are carried out in the EU. Usually the average duration of CT from start to marketing is 7.5 years, however, more than 80% of CT are delayed from 1 to 6 month costing to the companies upwards of 30,000 € per day per trial. In most of the cases, this delay is due to inefficient management systems. With CT conducted in over 140 countries, the complexity and rate of change in trials is increasing. Considering this huge business opportunity, we have been working in a customizable software system to manage and simplify CT development. iMOTED platform will ensure high quality data, collected from multiple sources by using real time analysis of data, a simple and intuitive interface, generation of real time alarms employing estimations, predictions & simulations
In this way, we expect to reduce the economic losses that pharma industry has when launching a new drug, for whom only 2 out of 10 marketed drugs return revenues that exceed R&D costs.
iMOTED belongs to the e-clinic market, which is forecasted to reach €7.6 Bn by 2022 growing at a CARG of 12.4% over the period 2017-2022. We will initially target Europe as our domestic market, to start selling the IMOTED licenses. We expect to have our breakeven point two years after the beginning of the project, a cumulative turnover of €13 M by 2022, that will give us a ROI of 560% in 2024. Hence, at this stage of development we believe that we need to perform a through feasibility study to assess for the challenges and tasks that we still must accomplish to launch iMOTED for what we are asking for EC support.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Noreste País Vasco Gipuzkoa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00